Previous studies have linked metabolic syndrome (MetS) to dementia risk.
Objective
We conducted a systematic review and meta-analysis to assess the association between MetS and dementia as well as cognitive impairment, with additional focus on individual MetS components.
Methods
We systematically searched the PubMed, Embase, and Cochrane Library databases from inception through July 2024. We used random-effects models to calculate relative risks (RRs) and odds ratios (ORs) with 95% confidence intervals (CIs). Publication bias was evaluated using the Egger's test, while potential sources of heterogeneity were investigated through meta-regression, subgroup, and sensitivity analyses.
Results
Our analysis included 21 studies with a total of 411,810 participants. MetS was associated with increased risks of all-cause dementia (RR = 1.33, 95% CI = 1.03–1.71, I² = 85.8%) and vascular dementia (RR = 2.07, 95% CI = 1.32–3.24, I² = 10.1%), but not Alzheimer's disease (RR = 1.10, 95% CI = 0.64–1.91, I² = 81.8%). Regarding cognitive impairment, longitudinal studies showed an increased risk (OR = 1.38, 95% CI = 1.24–1.53, I² = 3.3%), with similar findings in cross-sectional studies (OR = 1.65, 95% CI = 1.19–2.28, I² = 85.3%).
Conclusions
This study found that MetS is significantly associated with increased risks of dementia and cognitive impairment, with each component potentially being a modifiable factor. These findings may help guide clinicians in recommending lifestyle interventions to prevent cognitive decline and promote brain health.
AlbertiKGEckelRHGrundySM, et al.Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American Heart Association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation2009; 120: 1640–1645.
2.
CornierMADabeleaDHernandezTL, et al.The metabolic syndrome. Endocr Rev2008; 29: 777–822.
3.
SchererTSakamotoKBuettnerC. Brain insulin signalling in metabolic homeostasis and disease. Nat Rev Endocrinol2021; 17: 468–483.
4.
RohmTVMeierDTOlefskyJM, et al.Inflammation in obesity, diabetes, and related disorders. Immunity2022; 55: 31–55.
5.
LewisGFHegeleRA. Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia. Lancet Diabetes Endocrinol2022; 10: 142–148.
6.
CervellatiCWoodPLRomaniA, et al.Oxidative challenge in Alzheimer's disease: state of knowledge and future needs. J Investig Med2016; 64: 21–32.
7.
CervellatiCTrentiniAPecorelliA, et al.Inflammation in neurological disorders: the thin boundary between brain and periphery. Antioxid Redox Signal2020; 33: 191–210.
8.
KimOYSongJ. Important roles of linoleic acid and α-linolenic acid in regulating cognitive impairment and neuropsychiatric issues in metabolic-related dementia. Life Sci2024; 337: 122356.
9.
FerriCPPrinceMBrayneC, et al.Global prevalence of dementia: a Delphi consensus study. Lancet2005; 366: 2112–2117.
10.
YaffeKKanayaALindquistK, et al.The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA2004; 292: 2237–2242.
11.
MillerKLAlfaro-AlmagroFBangerterNK, et al.Multimodal population brain imaging in the UK biobank prospective epidemiological study. Nat Neurosci2016; 19: 1523–1536.
12.
YaffeKWestonALBlackwellT, et al.The metabolic syndrome and development of cognitive impairment among older women. Arch Neurol2009; 66: 324–328.
13.
RobertsROGedaYEKnopmanDS, et al.Metabolic syndrome, inflammation, and nonamnestic mild cognitive impairment in older persons: a population-based study. Alzheimer Dis Assoc Disord2010; 24: 11–18.
14.
FrisardiVSolfrizziVCapursoC, et al.Is insulin resistant brain state a central feature of the metabolic-cognitive syndrome?J Alzheimers Dis2010; 21: 57–63.
15.
AttiARValenteSIodiceA, et al.Metabolic syndrome, mild cognitive impairment, and dementia: a meta-analysis of longitudinal studies. Am J Geriatr Psychiatry2019; 27: 625–637.
16.
Machado-FraguaMDFayosseAYerramallaMS, et al.Association of metabolic syndrome with incident dementia: role of number and age at measurement of components in a 28-year follow-up of the Whitehall II Cohort Study. Diabetes Care2022; 45: 2127–2135.
17.
QureshiDCollisterJNEA, et al.Association between metabolic syndrome and risk of incident dementia in UK Biobank. Alzheimers Dement2024; 20: 447–458.
18.
LivingstonGHuntleyJSommerladA, et al.Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet2020; 396: 413–446.
19.
BorshchevYYUspenskyYPGalagudzaMM. Pathogenetic pathways of cognitive dysfunction and dementia in metabolic syndrome. Life Sci2019; 237: 116932.
20.
BiesselsGJDespaF. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol2018; 14: 591–604.
AlagiakrishnanKMahDAhmedA, et al.Cognitive decline in heart failure. Heart Fail Rev2016; 21: 661–673.
23.
PendleburySTRothwellPM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol2009; 8: 1006–1018.
24.
MillerAASpencerSJ. Obesity and neuroinflammation: a pathway to cognitive impairment. Brain Behav Immun2014; 42: 10–21.
25.
BoothAClarkeMDooleyG, et al.The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev2012; 1: 2.
26.
MoherDLiberatiATetzlaffJ, et al.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med2009; 6: e1000097.
27.
GrantRL. Converting an odds ratio to a range of plausible relative risks for better communication of research findings. BMJ2014; 348: f7450.
CumpstonMLiTPageMJ, et al.Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for systematic reviews of interventions. Cochrane Database Syst Rev2019; 10: ED000142.
30.
HigginsJPThompsonSG. Quantifying heterogeneity in a meta-analysis. Stat Med2002; 21: 1539–1558.
31.
SeagroattVStrattonI. Bias in meta-analysis detected by a simple, graphical test. Test had 10% false positive rate. BMJ1998; 316: 470. author reply 470–471.
32.
AltmanDGBlandJM. Interaction revisited: the difference between two estimates. BMJ2003; 326: 219.
33.
WilsonKHawkenS. Drug safety studies and measures of effect using the self-controlled case series design. Pharmacoepidemiol Drug Saf2013; 22: 108–110.
34.
ChaimaniAMavridisDSalantiG. A hands-on practical tutorial on performing meta-analysis with stata. Evid Based Ment Health2014; 17: 111–116.
35.
MullerMTangMXSchupfN, et al.Metabolic syndrome and dementia risk in a multiethnic elderly cohort. Dement Geriatr Cogn Disord2007; 24: 185–192.
36.
RaffaitinCGinHEmpanaJP, et al.Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the three-city study. Diabetes Care2009; 32: 169–174.
37.
FortiPPisacaneNRiettiE, et al.Metabolic syndrome and risk of dementia in older adults. J Am Geriatr Soc2010; 58: 487–492.
38.
SolfrizziVScafatoECapursoC, et al.Metabolic syndrome and the risk of vascular dementia: the Italian longitudinal study on ageing. J Neurol Neurosurg Psychiatry2010; 81: 433–440.
39.
CreavinSTGallacherJBayerA, et al.Metabolic syndrome, diabetes, poor cognition, and dementia in the Caerphilly prospective study. J Alzheimers Dis2012; 28: 931–939.
40.
FanYCChouCCYouSL, et al.Impact of worsened metabolic syndrome on the risk of dementia: a nationwide cohort study. J Am Heart Assoc2017; 6: e004749.
41.
ChoYHanKKimDH, et al.Cumulative exposure to metabolic syndrome components and the risk of dementia: a nationwide population-based study. Endocrinol Metab (Seoul)2021; 36: 424–435.
42.
HoRCNitiMYapKB, et al.Metabolic syndrome and cognitive decline in Chinese older adults: results from the Singapore longitudinal ageing studies. Am J Geriatr Psychiatry2008; 16: 519–522.
43.
ViscogliosiGDonfrancescoCPalmieriL, et al.The metabolic syndrome and 10-year cognitive and functional decline in very old men. A population-based study. Arch Gerontol Geriatr2017; 70: 62–66.
44.
LiuCYZhouHDXuZQ, et al.Metabolic syndrome and cognitive impairment amongst elderly people in Chinese population: a cross-sectional study. Eur J Neurol2009; 16: 1022–1027.
45.
VieiraJRElkindMSMoonYP, et al.The metabolic syndrome and cognitive performance: the Northern Manhattan Study. Neuroepidemiology2011; 37: 153–159.
46.
LuoLYangMHaoQ, et al.Cross-sectional study examining the association between metabolic syndrome and cognitive function among the oldest old. J Am Med Dir Assoc2013; 14: 105–108.
47.
ChenBJinXGuoR, et al.Metabolic syndrome and cognitive performance among Chinese ≥50 years: a cross-sectional study with 3988 participants. Metab Syndr Relat Disord2016; 14: 222–227.
48.
LiPQuanWLuD, et al.Association between metabolic syndrome and cognitive impairment after acute ischemic stroke: a cross-sectional study in a Chinese population. PLoS One2016; 11: e0167327.
49.
BaeSShimadaHLeeS, et al.The relationships between components of metabolic syndrome and mild cognitive impairment subtypes: a cross-sectional study of Japanese older adults. J Alzheimers Dis2017; 60: 913–921.
50.
FeinkohlIJankeJHadzidiakosD, et al.Associations of the metabolic syndrome and its components with cognitive impairment in older adults. BMC Geriatr2019; 19: 77.
51.
WangXJiLTangZ, et al.The association of metabolic syndrome and cognitive impairment in Jidong of China: a cross-sectional study. BMC Endocr Disord2021; 21: 40.
52.
SiervoMHarrisonSLJaggerC, et al.Metabolic syndrome and longitudinal changes in cognitive function: a systematic review and meta-analysis. J Alzheimers Dis2014; 41: 151–161.
53.
ZuinMRonconLPassaroA, et al.Metabolic syndrome and the risk of late onset Alzheimer's disease: an updated review and meta-analysis. Nutr Metab Cardiovasc Dis2021; 31: 2244–2252.
BiesselsGJStaekenborgSBrunnerE, et al.Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol2006; 5: 64–74.
56.
MielkeMMZandiPPShaoH, et al.The 32-year relationship between cholesterol and dementia from midlife to late life. Neurology2010; 75: 1888–1895.
57.
Van DykenPLacosteB. Impact of metabolic syndrome on neuroinflammation and the blood-brain barrier. Front Neurosci2018; 12: 930.
58.
González-DomínguezRGarcía-BarreraTVitoricaJ, et al.Metabolomic investigation of systemic manifestations associated with Alzheimer's disease in the APP/PS1 transgenic mouse model. Mol Biosyst2015; 11: 2429–2440.
59.
VanhanenMKoivistoKMoilanenL, et al.Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology2006; 67: 843–847.
60.
HendersonGC. Plasma free fatty acid concentration as a modifiable risk factor for metabolic disease. Nutrients2021; 13: 2590.
61.
Al-KuraishyHMJabirMSAlbuhadilyAK, et al.The link between metabolic syndrome and Alzheimer disease: a mutual relationship and long rigorous investigation. Ageing Res Rev2023; 91: 102084.
62.
Al-KuraishyHMAl-GareebAIAlsayeghAA, et al.A potential link between visceral obesity and risk of Alzheimer's disease. Neurochem Res2023; 48: 745–766.
63.
WhitmerRAGustafsonDRBarrett-ConnorE, et al.Central obesity and increased risk of dementia more than three decades later. Neurology2008; 71: 1057–1064.
64.
MaYAjnakinaOSteptoeA, et al.Higher risk of dementia in English older individuals who are overweight or obese. Int J Epidemiol2020; 49: 1353–1365.
65.
AndersonTSharmaSKelbermanMA, et al.Obesity during preclinical Alzheimer's disease development exacerbates brain metabolic decline. J Neurochem2024; 168: 801–821.
66.
AlroujiMAl-KuraishyHMAl-GareebAI, et al.The potential role of human islet amyloid polypeptide in type 2 diabetes mellitus and Alzheimer's diseases. Diabetol Metab Syndr2023; 15: 101.
67.
MichikawaM. Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease?J Neurosci Res2003; 72: 141–146.
68.
ReitzCTangMXSchupfN, et al.Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Arch Neurol2010; 67: 1491–1497.
69.
SharmaABemisMDesiletsAR. Role of medium chain triglycerides (Axona®) in the treatment of mild to moderate Alzheimer's disease. Am J Alzheimers Dis Other Demen2014; 29: 409–414.
70.
WalkerKASharrettARWuA, et al.Association of midlife to late-life blood pressure patterns with incident dementia. JAMA2019; 322: 535–545.
71.
RönnemaaEZetheliusBLannfeltL, et al.Vascular risk factors and dementia: 40-year follow-up of a population-based cohort. Dement Geriatr Cogn Disord2011; 31: 460–466.
72.
FaracoGParkLZhouP, et al.Hypertension enhances Aβ-induced neurovascular dysfunction, promotes β-secretase activity, and leads to amyloidogenic processing of APP. J Cereb Blood Flow Metab2016; 36: 241–252.
73.
RazayGVreugdenhilAWilcockG. The metabolic syndrome and Alzheimer disease. Arch Neurol2007; 64: 93–96.
74.
ArshadNLinTSYahayaMF. Metabolic syndrome and its effect on the brain: possible mechanism. CNS Neurol Disord Drug Targets2018; 17: 595–603.
75.
ErkinjunttiTOstbyeTSteenhuisR, et al.The effect of different diagnostic criteria on the prevalence of dementia. N Engl J Med1997; 337: 1667–1674.
76.
WetterlingTKanitzRDBorgisKJ. Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN). Stroke1996; 27: 30–36.
77.
QureshiDLubenRHayatS, et al.Role of age and exposure duration in the association between metabolic syndrome and risk of incident dementia: a prospective cohort study. Lancet Healthy Longev2024; 5: 100652.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
